FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128496509> ?p ?o ?g. }

• W3128496509 endingPage "2400" @default.
• W3128496509 startingPage "2398" @default.
• W3128496509 abstract "We read with great interest the recent publication from Ungaro and colleagues,1 reporting the latest data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) registry. These data, while raising concerns regarding the use of thiopurine and corticosteroid therapy in the SARS-CoV-2 pandemic, also provide valuable reassurance that monotherapy with anticytokine therapies, in particular those directed against tumour necrosis factor (TNF), are not associated with adverse outcomes in patients with IBD developing COVID-19. It has been postulated that anticytokine therapies may ameliorate or abrogate the ‘cytokine storm’ associated with severe COVID-19,2 with anti-IL6 strategies now approved for use.3We have assessed the SARS-CoV-2 antibody seroprevalence in patients with IBD, receiving either intravenous anti-TNF therapy, or anti-integrin therapy, during the first wave of the pandemic in the UK.Sera from 640 patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at the John Radcliffe Hospital (Oxford, UK) and Royal London Hospital (London, UK) were tested using the Abbott SARS-CoV-2 IgG assay. Adults (180) and paediatric (56) patients were included from London. Demographic and clinical data are summarised (online supplemental tables 1, 2). Key differences between the Oxford and London adult cohorts included ethnicity, smoking, comorbidities, disease type, concomitant thiopurines and biologic; in our data set, patients attending Royal London Hospital had significantly greater evidence for deprivation than Oxford (deprivation score 4 (3–6.3) vs 8 (6–9.3), p<0.001). Seroprevalence data were compared with available data from a contemporaneous healthy healthcare worker (HCW) …" @default.
• W3128496509 created "2021-02-15" @default.
• W3128496509 creator A5013854517 @default.
• W3128496509 creator A5019874037 @default.
• W3128496509 creator A5029546143 @default.
• W3128496509 creator A5030279523 @default.
• W3128496509 creator A5031083181 @default.
• W3128496509 creator A5038988225 @default.
• W3128496509 creator A5042117845 @default.
• W3128496509 creator A5052173273 @default.
• W3128496509 creator A5055734737 @default.
• W3128496509 creator A5056474210 @default.
• W3128496509 creator A5069131028 @default.
• W3128496509 creator A5073568142 @default.
• W3128496509 creator A5087925111 @default.
• W3128496509 date "2021-02-12" @default.
• W3128496509 modified "2023-09-30" @default.
• W3128496509 title "Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic" @default.
• W3128496509 cites W3012421327 @default.
• W3128496509 cites W3044919836 @default.
• W3128496509 cites W3080825697 @default.
• W3128496509 cites W3081411221 @default.
• W3128496509 cites W3094105410 @default.
• W3128496509 cites W3119648922 @default.
• W3128496509 doi "https://doi.org/10.1136/gutjnl-2021-324116" @default.
• W3128496509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33579788" @default.
• W3128496509 hasPublicationYear "2021" @default.
• W3128496509 type Work @default.
• W3128496509 sameAs 3128496509 @default.
• W3128496509 citedByCount "8" @default.
• W3128496509 countsByYear W31284965092021 @default.
• W3128496509 countsByYear W31284965092022 @default.
• W3128496509 countsByYear W31284965092023 @default.
• W3128496509 crossrefType "journal-article" @default.
• W3128496509 hasAuthorship W3128496509A5013854517 @default.
• W3128496509 hasAuthorship W3128496509A5019874037 @default.
• W3128496509 hasAuthorship W3128496509A5029546143 @default.
• W3128496509 hasAuthorship W3128496509A5030279523 @default.
• W3128496509 hasAuthorship W3128496509A5031083181 @default.
• W3128496509 hasAuthorship W3128496509A5038988225 @default.
• W3128496509 hasAuthorship W3128496509A5042117845 @default.
• W3128496509 hasAuthorship W3128496509A5052173273 @default.
• W3128496509 hasAuthorship W3128496509A5055734737 @default.
• W3128496509 hasAuthorship W3128496509A5056474210 @default.
• W3128496509 hasAuthorship W3128496509A5069131028 @default.
• W3128496509 hasAuthorship W3128496509A5073568142 @default.
• W3128496509 hasAuthorship W3128496509A5087925111 @default.
• W3128496509 hasBestOaLocation W31284965091 @default.
• W3128496509 hasConcept C116675565 @default.
• W3128496509 hasConcept C126322002 @default.
• W3128496509 hasConcept C159047783 @default.
• W3128496509 hasConcept C159654299 @default.
• W3128496509 hasConcept C203014093 @default.
• W3128496509 hasConcept C2776207728 @default.
• W3128496509 hasConcept C2777138892 @default.
• W3128496509 hasConcept C2778494684 @default.
• W3128496509 hasConcept C2779134260 @default.
• W3128496509 hasConcept C2779280984 @default.
• W3128496509 hasConcept C3006700255 @default.
• W3128496509 hasConcept C3007834351 @default.
• W3128496509 hasConcept C3008058167 @default.
• W3128496509 hasConcept C45189115 @default.
• W3128496509 hasConcept C524204448 @default.
• W3128496509 hasConcept C71924100 @default.
• W3128496509 hasConcept C89623803 @default.
• W3128496509 hasConceptScore W3128496509C116675565 @default.
• W3128496509 hasConceptScore W3128496509C126322002 @default.
• W3128496509 hasConceptScore W3128496509C159047783 @default.
• W3128496509 hasConceptScore W3128496509C159654299 @default.
• W3128496509 hasConceptScore W3128496509C203014093 @default.
• W3128496509 hasConceptScore W3128496509C2776207728 @default.
• W3128496509 hasConceptScore W3128496509C2777138892 @default.
• W3128496509 hasConceptScore W3128496509C2778494684 @default.
• W3128496509 hasConceptScore W3128496509C2779134260 @default.
• W3128496509 hasConceptScore W3128496509C2779280984 @default.
• W3128496509 hasConceptScore W3128496509C3006700255 @default.
• W3128496509 hasConceptScore W3128496509C3007834351 @default.
• W3128496509 hasConceptScore W3128496509C3008058167 @default.
• W3128496509 hasConceptScore W3128496509C45189115 @default.
• W3128496509 hasConceptScore W3128496509C524204448 @default.
• W3128496509 hasConceptScore W3128496509C71924100 @default.
• W3128496509 hasConceptScore W3128496509C89623803 @default.
• W3128496509 hasFunder F4320309446 @default.
• W3128496509 hasIssue "12" @default.
• W3128496509 hasLocation W31284965091 @default.
• W3128496509 hasOpenAccess W3128496509 @default.
• W3128496509 hasPrimaryLocation W31284965091 @default.
• W3128496509 hasRelatedWork W3017171836 @default.
• W3128496509 hasRelatedWork W3025176011 @default.
• W3128496509 hasRelatedWork W3027835066 @default.
• W3128496509 hasRelatedWork W3032320397 @default.
• W3128496509 hasRelatedWork W3033635008 @default.
• W3128496509 hasRelatedWork W3180778739 @default.
• W3128496509 hasRelatedWork W4280491013 @default.
• W3128496509 hasRelatedWork W4308017287 @default.
• W3128496509 hasRelatedWork W3107152225 @default.
• W3128496509 hasRelatedWork W3183300108 @default.
• W3128496509 hasVolume "70" @default.

• next